Sanofi is a global vaccine company with a long history of vaccine development for more than 120 years. Annually, Sanofi provides more than 1 billion doses immunization benefits to 500 million people and supply a wide range of vaccines over 17 infectious diseases (cholera, diphtheria, polio, pertussis, tetanus, hepatitis A, hepatitis B, meningococcal meningitis, influenza etc.).

Sanofi has a history of developing vaccines to prevent meningococcal meningitis disease for more than 40 years and is the world's largest influenza vaccine supplier with a history of influenza vaccine development for more than 50 years. Sanofi is supplying flu vaccines to more than 150(about 66%) of 227 countries worldwide.

MAT-KR-2200430-1.0-03/2022

Hexaxim Prefilled Syringe® is a hexavalent combination vaccine used for primary vaccination in infants for the prevention of six infectious diseases with a single dose. This 6-in-1 vaccine, an advancement on a pentavalent vaccine(Pentaxim) with the incorporation of the recombinant hepatitis B antigen developed by Sanofi Pasteur, gives protection against six invasive diseases caused by diphtheria, tetanus, pertussis, hepatitis B, polio, and Hib (Haemophilus influenza type b). It is given in three doses at 2, 4, and 6 months in infants vaccinated against hepatitis B at birth.

Hexaxim improves the convenience of vaccination by reducing the number of injections and hospital visits and helps to ensure timely inoculation by reducing dosing delays or omissions. It also increases the efficiency and convenience of vaccination as a fully liquid ready-to-use prefilled syringe that can be used immediately without the need of reconstitution.

Since its first marketing approval in Europe in 2013, more than 155 million doses of Hexaxim have been used in 125 countries over the past decade(as of March 2022). Hexaxim occupies a 67% market share in the hexavalent combination vaccine market in the top 40 countries that account for 96% of the global hexavalent combination vaccine use, and it accounts for 60%, or more than 2.3 million doses out of about 3.8 million doses of hexavalent combination vaccines given to preterm infants in 33 countries(as of 2020).

Hexavalent combination vaccines have been recommended for use worldwide. The vaccines are recommended in the national immunization program in more than 40 countries, including Europe, Canada, and Australia.
Meanwhile, Hexaxim has been used as a paid vaccine in Korea since approval in 2020.

MAT-KR-2201247-1.0-06/2022